**Supplemental Digital Content 4a**: Vaccination response at 5 months

|  |  |  |  |
| --- | --- | --- | --- |
|  | all anti-TNF α n | Adalimumab n | Infliximab n |
| Age of measurement response to vaccination in month# | 5.00 (5.00-8.00) 15 | 5.25 (5.00-6.50) 3 | 5.69 (5.00-8.00) 12 |
| Gestational age at birth in weeks# | 38.7(33.9-40.3) 18 | 36.9 (35.1-40.3) 3 | 38.7(33.9-40.1) 15 |
| Interval use anti-TNFα and birth in weeks# | 10.6 (0-15.1) 14 | 4.9 (2.3-15.1) 3 | 10.7 (0-15.1) 11 |
| Anti-TNFα concentration at birth (μg/ml)# | 7.65 (0.10-28.0) 13 | 10.35 (6.70-14.00) 2 | 8.60 (0.10-39.00) 11 |
| Pneu 6B μg/ml ^  Pneu 6B <0.35 μg/ml\* | 0.54 (0.01-6.00) 17  4 (24%) | 0.03(0.01-0.08) 3  3 (100%) | 0.99 (0.039-6.00) 14  1 (7%) |
| Pneu 9V μg/ml ^  Pneu 9V <0.35 μg/ml\* | 1.16 (0.01-14.00) 18  4 (22%) | 0.12 (0.02-2.50) 3  2 (67%) | 1.81 (0.01-14.00) 15  2 (13%) |
| Pneu 19F µg/ml ^  Pneu 19F <0.35 µg/ml\* | 3.54 (0.13-26.00) 18  3 (17%) | 2.75 (0.31-8.60) 3  1 (33%) | 3.73 (0.13-26.00) 15  2 (13%) |
| Hib PRP µg/ml^  Hib PRP < 1.0 µg /ml\* | 3.65 (0.23-32.5) 17  3 (18%) | 0.78 (0.23-3.00) 3  1 (33%) | 5.09 (0.80-32.50) 14  2 (14%) |
| Pertussis PT^  Pertussis PT <20 IU/ml\* or inadequate& | 46.76 (11.2-133) 13  3 (19%) 16 | 17.80 (11.2-28.3) 2  2 (67%) (n=3) | 55.74 (21.2-133) 11  1 (8%) 13 |

#;median with range, ^;Geometric mean IgG antibody concentrations, \*;number and percentage of children with concentrations below indicated protective thresholds. &;In 3 infants the laboratory reported outcome of titers to Pertussis only as either adequate, intermediate or inadequate, without providing a titer.**Supplemental Digital Content 4B.** Vaccination response at 12 months

|  |  |  |  |
| --- | --- | --- | --- |
|  | All anti TNF α n | Adalimumab n | Infliximab n |
| Age measurement response to vaccination in month# | 12.00 (11.50-16.00) 9 | 12.00 (11.50-12.50) 2 | 12 (12.00-16.00) 7 |
| Gestational age at birth in weeks# | 38.3 (37-41.4) 9 | 38.7(38.3-39.1) 2 | 38.3(37- 41.4) 7 |
| Interval use anti-TNFα and birth in weeks# | 10.9 (2.3-21.4) 9 | 2.3 1 | 11 (5.1-21.4) 8 |
| Anti-TNFα concentration at birth (μg/ml)# | 6.30 (0.20-15.00) 9 | 5.50 (5.40-5.60) 2 | 7.00 (0.2-15.00) 7 |
| Pneu 6B μg/ml^  Pneu 6B <0.35 μg/ml\* | 5.45 (1.40-35.0) 9  0 (0%) | 6.96 (5.50-8.80) 2  0 (0%) | 5.08 (1.40-35.00) 7  0 (0%) |
| Pneu 9V μg/ml^  Pneu 9V <0.35 µg/ml\* | 5.17 (1.10-41.00) 9  0 (0%) | 7.96 (6.40-9.90) 2  0 (0%) | 1.10-41.00 7  0 (0%) |
| Pneu 19F μg/ml^  Pneu 19F <0.35 µg/ml\* | 14.88 (2.40-41.00) 9  0 (0%) | 9.92 (2.40-41.00) 2  0 (0%) | 16.70 (7.40-41.00) 7  0 (0%) |
| Hib PRP µg /ml^  Hib PRP < 1.0 μg/ml\* | 4.72 (0.33-9.00) 9  1 (11%)\*\*\* 9 | 9.00 (9.00-9.00) 2  0 (0%) | 3.92 (0.33-9.00) 7  1 (14%)\*\*\* 7 |
| Pertussis PT IU/ml^  Pertussis PT Inadequate& | 40.00 1  1 (33.3%) 3 | - | 40.00 1  1 (33.3%) 3 |

#;median with range, ^;Geometric mean IgG antibody concentrations, \*;number and percentage of children with concentrations below indicated protective thresholds. &;In 3 infants the laboratory reported outcome of titers to Pertussis only as either adequate, intermediate or inadequate, without providing a titer